Supernus receives FDA approval for ONAPGO as first subcutaneous apomorphine infusion device for Parkinson's

SUPERNUS PHARMACEUTICALS, INC.

ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.
Phase 3 study: ONAPGO reduced daily OFF time by 2.6 hours vs 0.9 hours placebo (p=0.0114); GOOD ON time increased 2.8 vs 1.1 hours.
Product will be available in the U.S. in Q2 2025, with a support team including nurse education programs.
Most common adverse events (≥10%): infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, insomnia.
CEO Jack Khattar stated ONAPGO demonstrates Supernus' continued commitment to CNS innovation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.